Dutasteride
- TRADE NAMES: Avodart (GSK); Jalyn (GSK)
- INDICATIONS: Benign prostatic hyperplasia; male pattern baldness (anecdotal)
- CLASS: 5-alpha reductase inhibitor, Androgen antagonist
- HALF-LIFE: 3–5 weeks
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cimetidine, Ciprofloxacin, Conivaptan, Darunavir, Delavirdine, Diltiazem, Indinavir, Ketoconazole, Ritonavir, Telithromycin, Troleandomycin, Verapamil, Voriconazole
PREGNANCY CATEGORY: X
Jalyn is dutasteride and tamsulosin.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dutasteride in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric